The Delhi High Court ordered the removal of Razenta Pharmaceuticals' Daplogin trademark. This decision came as the mark was deemed deceptively similar to Dr Reddy's Labs' Daplo trademark. Both trademarks are used for prescription drugs treating Type-2 diabetes Mellitus. The court cited phonetic similarity and potential consumer confusion as key reasons. Razenta's trademark registration was cancelled within six weeks by the court.